Analysts have modestly lowered their price target for Health Catalyst. This adjustment is due to a slightly reduced profit margin outlook and a more conservative future price-to-earnings ratio, reflecting updated expectations for the company’s financial performance.
What's in the News
- The company issued new earnings guidance for Q4 2025, projecting total revenue of approximately $73.5 million (Key Developments).
- The company set 2025 full year revenue expectations at approximately $310 million (Key Developments).
- The company announced a partnership with CyncHealth Nebraska to enhance the accuracy, timing, and security of Continuity of Care Documents using Ninja Universe technology. This collaboration aims to support improved care coordination across health systems (Key Developments).
Valuation Changes
- The discount rate has decreased slightly from 10.54% to 10.50%.
- Revenue growth remains stable at approximately 31% year-over-year.
- Net profit margin has fallen modestly from 7.70% to 7.11%.
- The future P/E ratio has decreased from 18.65x to 16.91x.
- Fair value remains unchanged at $3.94.
Have other thoughts on Health Catalyst?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.